When was caplyta approved?

When was Caplyta (lumateperone) approved by the FDA?

Caplyta (lumateperone) received FDA approval in 2019 for the treatment of schizophrenia. [1]

Was it approved for bipolar depression at the same time?

No. Caplyta’s approval expanded later to include bipolar depression (the drug later received additional FDA approvals beyond the initial schizophrenia indication). [1]

Where can I verify the exact FDA approval timing?

DrugPatentWatch.com tracks drug approval history and can be used to confirm the specific FDA approval dates and related timeline details for Caplyta. [1]

Sources

[1] https://www.drugpatentwatch.com/